Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227320 | 1.00 | LPL (0.44) | LPLLIPGCYP1A2POLBHIF1A | |
| SCHEMBL16465738 | 0.87 | LPL (0.53) | LPLLIPGGSK3AGSK3B | |
| SCHEMBL15984293 | 0.85 | LIPG (0.39) | LPLLIPGHIF1AGSK3AGSK3B | |
| SCHEMBL31469519 | 0.85 | LPL (0.40) | LPLLIPGF11FFAR1 | |
| SCHEMBL2427482 | 0.85 | LPL (0.40) | LPLLIPGF11FFAR1 | |
| SCHEMBL17304237 | 0.84 | LPL (0.38) | LPLLIPGHIF1AF11 | |
| SCHEMBL18113825 | 0.81 | ESR2 (0.39) | LPLLIPGF11FFAR1 | |
| SCHEMBL2049952 | 0.79 | F11 (0.40) | LPLLIPGHIF1AGSK3AGSK3B | |
| SCHEMBL31198038 | 0.79 | LPL (0.44) | LPLLIPGF11FFAR1 | |
| SCHEMBL31705815 | 0.78 | CXCR4 (0.41) | LPLLIPGHIF1AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240124452-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2024-04-18 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| CN-116601150-A | Fused bicyclic RAF inhibitors and methods of use thereof | 爵士制药爱尔兰有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4188552-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | Jazz Pharmaceuticals Ireland Limited (IE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-02-03 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| WO-2011149874-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | SCHERING CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | LPL 4682/4885LIPG 3829/4885CYP1A2 2555/4885 |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | LPL 4682/4885LIPG 3829/4885CYP1A2 2555/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | LPL 3845/4885LIPG 4183/4885CYP1A2 1951/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | LPL 4682/4885LIPG 3829/4885CYP1A2 2555/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | LPL 3618/4885LIPG 3765/4885CYP1A2 4149/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | LPL 3942/4885LIPG 3515/4885CYP1A2 2622/4885 |
| US-20240124452-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | LPL 4682/4885LIPG 3829/4885CYP1A2 2555/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | LPL 4833/4885LIPG 4519/4885CYP1A2 1401/4885 |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | LPL 2200/4885LIPG 1355/4885CYP1A2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.